Core Viewpoint - The announcement details the implementation of the 2023 Restricted Stock Incentive Plan by Jiangsu Nuotai Aosaino Biopharmaceutical Co., Ltd, including the allocation of restricted stocks and their upcoming listing date. Group 1: Stock Listing and Allocation - The total number of stocks to be listed for circulation is 1,232,616 shares, with the listing date set for July 9, 2025 [1][7]. - The stock allocation includes 62 incentive recipients, with a total of 410.8720 million shares granted, representing 30% of the total granted shares [5][6]. Group 2: Decision-Making Process - The decision-making process for the stock allocation involved multiple meetings, including the approval of the incentive plan by the board and independent directors, as well as the verification of the incentive recipient list by the supervisory board [2][3][4]. Group 3: Financial Impact - Following the stock allocation, the total share capital will increase from 314,819,281 shares to 316,051,897 shares, with the new shares accounting for approximately 0.39% of the total share capital [10][11]. - The basic earnings per share (EPS) for 2024 will be diluted, calculated based on the new total share capital, while the net profit attributable to shareholders remains unchanged at 404,389,990.70 yuan [11].

Suspension and Resumption of Trading - *ST Yazhen has completed the stock price verification and will resume trading [1] - Changling Hydraulic's actual controller is planning a major event, leading to stock suspension [1] - Shangwa New Materials' controlling shareholder is planning a major event, resulting in continued stock suspension [1] Investment Cooperation and Operational Status - Vanke A has applied for a loan of no more than 6.249 billion yuan from Shenzhen Metro Group [2] - Hualing Steel has been lifted by Xintai Life Insurance, with a shareholding ratio reaching 5% [2] - Aerospace Chenguang has restored its procurement qualifications for military material engineering services [2] - China Oil Engineering's subsidiary has won a 2.121 billion yuan project from Total Energy in Iraq [2] - Shengde Xintai has won a steel pipe procurement project from Shanghai Boiler Factory, with a bid amount of approximately 217 million yuan [2] - Xingxin New Materials plans to invest 800 million yuan to construct a project with an annual output of 153,000 tons of polyolefin and polyamine series products [2] - China Nuclear Power expects to generate 115.104 billion kilowatt-hours of electricity in the first half of 2025, a year-on-year increase of 15.92% [2] Performance Changes - Brothers Technology expects a net profit of 60 million to 70 million yuan for the first half of the year, a year-on-year increase of 325.00% to 431.25%, driven by rising prices of some vitamin products [3] - Huayin Power expects a net profit attributable to shareholders of 180 million to 220 million yuan for the half-year, an increase of 175 million to 215 million yuan compared to the same period last year [3] - Nuotai Bio expects a net profit of 300 million to 330 million yuan for the first half of 2025, a year-on-year increase of 32.06% to 45.27% [3] - Yude Development expects a net profit of 175 million to 225 million yuan for the first half of the year, compared to a loss of 32.9 million yuan in the same period last year, mainly due to the transfer of 1% equity in Langfu Company and the recognition of investment income of 240 million yuan from the fair value remeasurement of remaining equity [3]

Core Viewpoint - The article discusses the recent fluctuations in the A-share market, highlighting the impact of U.S.-Vietnam trade agreements and the performance of specific sectors, particularly consumer electronics and innovative pharmaceuticals. Market Overview - The A-share market experienced a rebound, with the Shanghai Composite Index rising by 0.18%, the Shenzhen Component Index increasing by 1.17%, and the ChiNext Index up by 1.9% [5] - The total market turnover was 13,336 billion, a decrease of 716 billion from the previous day, with over 3,200 stocks rising [5] - A total of 66 stocks hit the daily limit up, with 14 stocks achieving consecutive limit ups, the highest being six consecutive limit ups [5] Sector Performance - The consumer electronics sector saw a collective surge, with stocks like Industrial Fulian, New Asia Electronics, and Chaoyang Technology hitting the daily limit up [5] - The PCB sector also rebounded, with stocks such as Zhongjing Electronics, Bomin Electronics, and Yihua New Materials reaching the daily limit up, driven by speculation on future demand for AI-PCB [5] - Innovative pharmaceutical stocks continued their strong performance, with companies like Guosheng Tang and Changchun High-tech also hitting the daily limit up [5] Trade Policy Impact - The U.S. has lifted restrictions on EDA and ethane exports to China, while Trump announced a trade agreement with Vietnam, which will impose a 20% tariff on Vietnamese exports to the U.S. [1][2] - This policy shift is seen as beneficial for consumer electronics companies with operations in Vietnam, such as Luxshare Precision, which had previously invested in production capacity there [2] Investment Trends - Morgan Stanley's MSCI China Index has risen by 32% over the past year, indicating a recovery in consumer spending and addressing overcapacity issues [7] - The article notes that the current market environment is conducive to a potential supply-side reform, with a focus on key sectors such as automotive, materials, and technology [8][9] Capital Market Dynamics - The article highlights that despite the return to average price-to-earnings ratios, the equity risk premium remains high, suggesting that the Chinese stock market is still undervalued [9] - The low interest rates are expected to continue, with predictions of further rate cuts, which could lead to a shift in investment towards growth stocks as overall return on equity improves [9]

证券代码：688076 证券简称：诺泰生物 公告编号：2025-056 江苏诺泰澳赛诺生物制药股份有限公司 关于 2023 年限制性股票激励计划 第二个归属期归属结果暨股份上市公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 本次股票上市类型为股权激励股份；股票认购方式为网下，上市股数为 1,232,616股。 本次股票上市流通总数为1,232,616股。 本次股票上市流通日期为2025 年 7 月 9 日。 江苏诺泰澳赛诺生物制药股份有限公司（以下简称"公司"）于近日收到中国 证券登记结算有限责任公司上海分公司出具的《证券变更登记证明》，公司已完成 2023 年限制性股票激励计划第二个归属期的股份归属登记工作。现将相关情况公 告如下: 一、本次限制性股票归属的决策程序及相关信息披露 1、2023 年 5 月 22 日，公司召开第三届董事会第十一次会议，会议审议通过 了《关于<公司 2023 年限制性股票激励计划（草案）>及其摘要的议案》《关于<公 司 2023 年限制性股票激励计划实施考核管理办法>的 ...

证券代码：688076 证券简称：诺泰生物 公告编号：2025-055 （二）业绩预告情况 （1）经财务部门初步测算，预计 2025 年半年度实现归属于母公司所有者的 净利润为 30,000 万元到 33,000 万元，与上年同期（法定披露数据）相比，将增 加 7,284 万元到 10,284 万元，同比增加 32.06%到 45.27%。 江苏诺泰澳赛诺生物制药股份有限公司 2025年半年度业绩预告的自愿性披露公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、本期业绩预告情况 （一）业绩预告期间 2025 年 1 月 1 日至 2025 年 6 月 30 日。 （2）预计 2025 年半年度实现归属于母公司所有者的扣除非经常性损益的净 利润为 30,000 万元到 33,000 万元，与上年同期（法定披露数据）相比，将增加 7,061 万元到 10,061 万元，同比增加 30.78%到 43.86%。 （三）本次业绩预告未经注册会计师审计。 二、上年同期业绩情况 2024 年半年度，公司利润总额：25,696 ...

诺泰生物公告，预计2025年半年度实现归属于母公司所有者的净利润为3亿元到3.3亿元，与上年同期相 比，将增加7284万元到1.03亿元，同比增加32.06%到45.27%。预计2025年半年度实现归属于母公司所有 者的扣除非经常性损益的净利润为3亿元到3.3亿元，与上年同期相比，将增加7061万元到1.01亿元，同 比增加30.78%到43.86%。 ...

Core Viewpoint - The healthcare services sector experienced a decline of 1.45% with a net outflow of 1,102.31 million in funds, indicating a bearish trend in the market [1] Group 1: Sector Performance - The healthcare services sector saw a total of 2 stocks rising and 41 stocks declining [1] - The top ten decliners in the sector included Sanbo Brain Science (-4.57%), Ruizhi Medicine (-4.56%), and Innovation Medical (-4.34%) [1] Group 2: Stock Details - Sanbo Brain Science closed at 49.87 with a decline of 4.57% and a net fund outflow of 108.09 million [1] - Ruizhi Medicine closed at 10.88, down 4.56%, with a net outflow of 68.69 million [1] - Innovation Medical closed at 15.00, down 4.34%, with a net outflow of 320.40 million [1] - Other notable decliners included Maipu Medical (-3.79%), Nuotai Biological (-3.40%), and Dae Oriental (-3.21%) [1] Group 3: Gainers - The stocks that gained included *ST Biological with an increase of 3.83% and Chengda Pharmaceutical with an increase of 1.03% [1]

登录新浪财经APP 搜索【信披】查看更多考评等级 经审议，监事会认为：鉴于公司2024年半年度以及2024年年度利润分配方案已实施完毕，公司董事会根 据2022年年度股东大会授权对2023年限制性股票激励计划的相关事项进行调整，审议程序合法合规，符 合《上市公司股权激励管理办法》等有关法律、法规、规范性文件和公司《2023年限制性股票激励计划 （草案）》的相关规定，不存在损害公司及全体股东利益的情形。因此，监事会同意本议案。 表决结果：同意3票，反对0票，弃权0票。 证券代码：688076 证券简称：诺泰生物 公告编号：2025-051 江苏诺泰澳赛诺生物制药股份有限公司 第四届监事会第二次会议决议公告 本公司监事会及全体监事保证公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容的 真实性、准确性和完整性依法承担法律责任。 江苏诺泰澳赛诺生物制药股份有限公司（以下简称"公司"）第四届监事会第二次会议于2025年6月26日 下午16:00以通讯会议方式召开，会议通知于2025年6月20日以电子邮件方式送达全体监事。本次会议应 出席监事3人，实际出席监事3人，会议由监事会主席殷新波先生主持。会议的召开 ...

Core Viewpoint - The legal opinion letter from Grandall Law Firm (Hangzhou) confirms that Jiangsu Nuotai Aosaino Biopharmaceutical Co., Ltd.'s 2023 restricted stock incentive plan has met the necessary conditions for the second vesting period, and the adjustments and cancellations of certain restricted stocks are compliant with relevant laws and regulations [2][20]. Group 1: Approval and Authorization - The company has received approval for the 2023 restricted stock incentive plan, with independent directors expressing agreement and no objections raised during the public notice period [6][9]. - The company’s supervisory board has verified that the proposed incentive objects meet the legal and regulatory requirements [7][9]. Group 2: Vesting Details - The second vesting period for the restricted stocks is defined as the first trading day after 24 months from the grant date until the last trading day within 36 months from the grant date, with 30% of the total granted rights eligible for vesting [10][12]. - The vesting conditions require that the company has not received negative audit opinions or failed to meet legal profit distribution requirements in the past 36 months [10][11]. Group 3: Adjustments - The grant price of the restricted stocks has been adjusted from 15.13 CNY per share to 10.1643 CNY per share due to capital increases and cash dividends [18]. - The number of restricted stocks granted has been adjusted from 1,518,750 shares to 2,126,250 shares based on the same factors [18]. Group 4: Cancellations - A total of 71,890 shares of restricted stock have been rendered void due to the departure of three incentive objects, which disqualified them from the incentive plan [19]. - The cancellation of these shares is in accordance with the provisions of the incentive plan regarding the treatment of unvested stocks upon employee departure [19]. Group 5: Conclusion - The legal opinion concludes that all aspects of the vesting, adjustments, and cancellations are in compliance with the Company Law, Securities Law, and relevant regulations, and the company will continue to fulfill its disclosure obligations [20].

江苏诺泰澳赛诺生物制药股份有限公司监事会 关于 2023 年限制性股票激励计划第二个归属期归属名 单的核查意见 江苏诺泰澳赛诺生物制药股份有限公司（以下简称"公司"）监事会依据《中 华人民共和国公司法》 （以下简称"《公司法》"）、 《中华人民共和国证券法》 除 3 名激励对象因离职丧失激励对象资格，不符合归属条件外，本次拟归属 的 62 名激励对象符合《公司法》 《证券法》等法律、法规和规范性文件以及《公 司章程》规定的任职资格，符合《上市公司股权激励管理办法》《上海证券交易 所科创板股票上市规则》等法律、法规和规范性文件规定的激励对象条件，符合 本次激励计划规定的激励对象范围，其作为公司本次限制性股票激励计划激励对 象的主体资格合法、有效，激励对象获授限制性股票的归属条件已成就。 监事会同意本次符合条件的 62 名激励对象办理归属，对应限制性股票的归 属数量为 123.2616 万股。上述事项符合相关法律、法规及规范性文件所规定的 条件，不存在损害公司及股东利益的情形。 特此公告。 江苏诺泰澳赛诺生物制药股份有限公司监事会 （以 下简称"《证券法》"）、 （以下简称"《管理办法》"）、 《上市公司股权激励 ...